Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Wassil Nowicky

Wassil Nowicky

Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria

Title: The antiangiogenic properties of NSC-631570 (Ukrain) on breast cancer

Biography

Biography: Wassil Nowicky

Abstract

One of important features of anti-cancer drug NSC‐631570 is the inhibition of the formation of the new blood vessels supplying a tumor. Due to these antiangiogenic properties NSC-631570 administered before surgery brings about better demarcation of the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been confirmed in breast cancer studies. In tests in vitro, NSC-631570 inhibited in a dose dependent manner the proliferation of human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation model. This inhibition of the neoangiogenesis prevents the metastasis formation as well.

 

The researchers from Emory University (Atlanta, Georgia, USA) and Kennesaw State University (Kennesaw, Georgia, USA) concluded: “The anticancer drug Ukrain exerts its cytotoxic effects on both mouse and human breast cancer cell lines in a dose and time dependent manner. Weeks following Ukrain treatment, cells maintained a reduced capacity to proliferate. Our data suggest that Ukrain could be effective as an anticancer drug for breast cancer due to its short term and long term inhibitory effects on tumor cell viability and proliferation.” This work was supported by RO1 CA‐138993 and the NSF Award # 0450303 Subaward # 1‐66‐606‐63.